Argenx’s investigational therapy, efgartigimod alfa, has been granted Promising Innovative Medicine status by the UK MHRA for treating CIDP. This autoimmune disorder affects around 650 people annually in the UK, leading to severe disability. Efgartigimod alfa aims to block harmful antibodies attacking nerve cells, offering hope for patients with limited treatment options. The therapy, already used for gMG, shows potential for CIDP as well. Argenx is working towards EAMS inclusion to bring relief to those in need. This recognition highlights the therapy’s promise in treating severe autoimmune diseases.
Source
Photo credit pharmatimes.com
